These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15270006)

  • 1. European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic.
    Winkler D; Kasper S
    IDrugs; 2003 Nov; 6(11):1020-3. PubMed ID: 15270006
    [No Abstract]   [Full Text] [Related]  

  • 2. Aripiprazole (Otsuka Pharmaceutical Co).
    Ozdemir V; Fourie J; Ozdener F
    Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abstracts of the 16th Congress of the European College of Neuropsychopharmacology. Prague, Czech Republic, September 20-24, 2003.
    Eur Neuropsychopharmacol; 2003 Sep; 13 Suppl 4():S93-488. PubMed ID: 14524345
    [No Abstract]   [Full Text] [Related]  

  • 4. Aripiprazole.
    Grady MA; Gasperoni TL; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Jun; 2(6):427-8. PubMed ID: 12790153
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
    Tsai SJ
    Med Hypotheses; 2004; 63(6):1047-50. PubMed ID: 15504573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
    Olincy A; Stevens KE
    Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
    Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
    Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    Paulzen M; Gründer G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):149-51. PubMed ID: 16942633
    [No Abstract]   [Full Text] [Related]  

  • 9. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial agonists in schizophrenia.
    Cousins DA; Young AH
    Br J Psychiatry; 2005 Apr; 186():354. PubMed ID: 15802697
    [No Abstract]   [Full Text] [Related]  

  • 13. Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists.
    McDonald IM; Mate RA; Zusi FC; Huang H; Post-Munson DJ; Ferrante MA; Gallagher L; Bertekap RL; Knox RJ; Robertson BJ; Harden DG; Morgan DG; Lodge NJ; Dworetzky SI; Olson RE; Macor JE
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1684-8. PubMed ID: 23414838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial agonism and schizophrenia.
    Bolonna AA; Kerwin RW
    Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
    [No Abstract]   [Full Text] [Related]  

  • 15. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
    Liemburg E; Aleman A; Bous J; Hollander K; Knegtering H
    Pharmacopsychiatry; 2011 May; 44(3):109-13. PubMed ID: 21432752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A; Steckler T
    Eur J Pharmacol; 2010 Aug; 639(1-3):2-16. PubMed ID: 20371230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic therapy over half a century: a tale of discovery from chlorpromazine to aripiprazole.
    Natesan S; Kapur S
    Natl Med J India; 2012; 25(4):193-5. PubMed ID: 23278774
    [No Abstract]   [Full Text] [Related]  

  • 19. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists.
    Jonnala RR; Buccafusco JJ
    J Neurosci Res; 2001 Nov; 66(4):565-72. PubMed ID: 11746376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.